Pfizer reports top-line results from phase 3 study evaluating pregabalin CR
Pfizer announced top-line results from a double-blind Phase 3 study evaluating pregabalin controlled-release formulation in adult patients with postherpetic neuralgia. The results show pregabalin CR resulted in a statistically significant positive effect compared to placebo in the primary endpoint. December 18, 2014